Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-12-19)Premium Content

Five Prime Therapeutics Inc (FPRX)

2015-01-22@03:58:28 ET
8-K: FIVE PRIME THERAPEUTICS INC (EDK)

2015-01-20@15:09:01 ET
Tuesday 1/20 Insider Buying Report: JPM, FPRX (MNV)

2015-01-17@05:19:50 ET
Form 4: Update Filing for Five Prime Therapeutics Inc (FPRX) (VKR)

2015-01-12@10:00:22 ET
Five Prime Therapeutics Announces Closing of Public Offering (PMZ)

2015-01-08@16:06:47 ET
Five Prime Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference (PMZ)

2015-01-07@19:09:45 ET
8-K: FIVE PRIME THERAPEUTICS INC (EDK)

2015-01-07@15:10:43 ET
Five Prime Therapeutics prices $75.02 million public offering of common stock (DTF)

2015-01-06@20:10:07 ET
Five Prime Therapeutics Prices Public Offering of Common Stock (PMZ)

2015-01-06@15:21:57 ET
Five Prime Therapeutics to raise $75 million in public offering of common stock (DTF)

2015-01-05@16:01:06 ET
Five Prime Announces $75 Million Proposed Public Offering of Common Stock (PMZ)

2014-12-05@21:00:27 ET
Five Prime Therapeutics, Inc.Corporate Event Announcement Notice (WSH)

2014-12-05@02:39:23 ET
Five Prime Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference (PMZ)

2014-12-04@21:00:09 ET
Five Prime Therapeutics, Inc.Corporate Event Announcement Notice (WSH)

2014-12-04@19:03:08 ET
8-K: FIVE PRIME THERAPEUTICS INC (EDK)

2014-12-04@16:05:27 ET
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial Evaluating FPA144 in Gastric Cancer (PMZ)

2014-12-03@11:22:13 ET
Form 4: Update Filing for Five Prime Therapeutics Inc (FPRX) (VKR)

2014-12-03@09:16:31 ET
Form 4: Update Filing for Five Prime Therapeutics Inc (FPRX) (VKR)

2014-12-03@06:49:01 ET
Form 4: Update Filing for Five Prime Therapeutics Inc (FPRX) (VKR)

2014-12-02@07:01:17 ET
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014 (MTO)

2014-11-28@09:30:00 ET
The Zacks Analyst Blog Highlights:BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex (PRN)